Blocking IL-13 activity with dupilumab leads to two major consequences: first, it inhibits the proliferation and function of goblet cells, resulting in decreased mucus production and barrier dysfunction, akin to that seen in dry eye disease; second, dupilumab induces a shift in the cytokine profile from a mixed Th2/Th17 to a Th1/Th17 pattern in AD patients who develop DAOSD. This evidence concerns the gene IL13 and Alzheimer disease.